Jim Cramer's Latest Stock Picks: Top Buys for 2026

Cramer's 2026 Focus: AI Infrastructure Stocks Like Nvidia and Broadcom

Jim Cramer's recent recommendations double down on artificial intelligence infrastructure, naming Nvidia and Broadcom as core holdings for 2026. He argues that the AI adoption cycle remains in its early stages, with enterprise deployment and edge computing set to drive demand for years to come.

"The AI trade is not over — we're still in the first inning of a nine-inning game," Cramer said on CNBC, pointing to Nvidia's next-generation Blackwell architecture and its commanding position in data center GPUs.

Nvidia's dominance in AI chips is undisputed, but Cramer also highlights Broadcom's custom accelerators and networking silicon as essential picks for diversified exposure. He acknowledges that valuation multiples are stretched but insists that earnings growth will justify the premiums. Investors seeking broader tech exposure can compare these picks with trends in the semiconductor sector, as detailed in our Samsung stock analysis.

• Nvidia benefits from Blackwell architecture and hyperscaler demand, with data center revenue expected to grow 50% year-over-year.
• Broadcom provides custom AI accelerators for cloud giants, plus a diversified portfolio in enterprise networking and software.
• Cramer warns that both stocks carry high valuations, but he sees the AI cycle as structural, not cyclical, recommending dollar-cost averaging.

Healthcare Picks: Why Cramer Loves Eli Lilly and Vertex Pharmaceuticals

In healthcare, Cramer is bullish on Eli Lilly and Vertex Pharmaceuticals, citing strong patent protections and expanding addressable markets. Eli Lilly's GLP-1 drugs — Mounjaro and Zepbound — are on track for blockbuster sales as approvals widen to include obesity, diabetes, and cardiovascular outcomes.

"Lilly has the best pipeline in pharma right now," Cramer stated, noting that the company's metabolic franchise could generate over $50 billion in peak annual revenue.

Vertex Pharmaceuticals offers a defensive growth profile with its monopoly in cystic fibrosis and a promising pipeline, including the non-opioid pain drug VX-548. Cramer emphasizes that these picks are less sensitive to economic cycles, providing portfolio ballast. He cautions, however, about potential pricing pressure from regulators and competition from upcoming biosimilars.

• Eli Lilly benefits from expanding GLP-1 indications, with new data on cardiovascular and kidney benefits driving prescription growth.
• Vertex holds a stable CF franchise and has positive Phase 3 results for VX-548 in acute pain.
• Both stocks trade at premium multiples, but Cramer argues their growth trajectories and patent cliffs (post-2030) justify the price.

Energy Transition Plays: Cramer Backs NextEra Energy and Enphase Energy

Cramer rounds out his 2026 picks with energy transition plays: NextEra Energy and Enphase Energy. NextEra, the world's largest wind and solar operator, benefits from declining renewable costs and the Inflation Reduction Act's tax credits. Enphase leads in microinverters and home energy storage, riding the growth of residential solar and grid resilience.

"The energy transition is not a fad — it's a permanent shift," Cramer noted, pointing to the 2024 Clean Power Plan and state-level mandates as catalysts.

Both stocks face headwinds from interest rate sensitivity, but Cramer believes the long-term demand for clean energy outweighs near-term volatility. He recommends starting small positions and adding on dips, especially if rates stabilize. Geopolitical risks to global supply chains, as examined in the Strait of Hormuz analysis, underscore the need for domestic energy infrastructure.

• NextEra Energy boasts a massive pipeline of wind/solar projects and regulated utility income, offering steady dividends and growth.
• Enphase Energy captures increasing residential solar and storage adoption, with its IQ8 microinverter technology enabling backup power.
• Cramer warns that falling interest rates are critical for these stocks, but he believes the secular trend toward renewable energy is irreversible.

Key Takeaways

• Cramer's 2026 picks emphasize structural growth themes: AI infrastructure, healthcare innovation, and energy transition.
• Investors should monitor valuation multiples, as high expectations are already priced into many of these stocks.
• Diversification across sectors is key: Nvidia and Broadcom for tech exposure, Lilly and Vertex for defensive healthcare, NextEra and Enphase for clean energy.
• Catalysts to watch include AI earnings beats, FDA approvals for drugs, and renewable energy capacity additions.
• Risks include geopolitical tensions, regulatory changes, and competition from emerging players.
• Cramer recommends dollar-cost averaging into these positions rather than lump-sum investments.